Literature DB >> 21249698

Surgical interventions for high grade vulval intraepithelial neoplasia.

Sonali Kaushik1, Litha Pepas, Andy Nordin, Andrew Bryant, Heather O Dickinson.   

Abstract

BACKGROUND: Vulval intraepithelial neoplasia (VIN) is a pre-malignant condition of the vulval skin. This uncommon chronic skin condition of the vulva is associated with a high risk of recurrence and the potential to progress to vulval cancer. The condition is complicated by its' multicentric and multifocal nature. The incidence of this condition appears to be rising particularly in the younger age group.There is a lack of consensus on the optimal surgical treatment method. However, the rationale for surgical treatment of VIN has been to treat symptoms and exclude underlying malignancy with the continued aim of preservation of vulval anatomy and function. Repeated treatments affect local cosmesis and cause psychosexual morbidity thus impacting on the patients' quality of life.
OBJECTIVES: To evaluate the effectiveness and safety of surgical interventions for high grade VIN. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Issue 3, 2010, Cochrane Gynaecological Cancer Group Trials Register, MEDLINE and EMBASE up to September 2010. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies and contacted experts in the field. SELECTION CRITERIA: Randomised controlled trials (RCTs) that compared surgical interventions, in adult women diagnosed with high grade vulval intraepithelial neoplasia. DATA COLLECTION AND ANALYSIS: Two review authors independently abstracted data and assessed risk of bias. MAIN
RESULTS: We found only one RCT which included 30 women that met our inclusion criteria and this trial reported data on carbon dioxide laser (CO(2) laser) versus ultrasonic surgical aspiration (USA).There was no statistically significant difference in the risk of disease recurrence after one year follow-up, pain, presence of scarring, dysuria or burning, adhesions, infection, abnormal discharge and eschar between women who received CO(2) laser and those who received USA. The trial lacked statistical power due to the small number of women in each group and the low number of observed events, but was at low risk of bias. AUTHORS'
CONCLUSIONS: The included trial lacked statistical power due to the small number of women in each group and the low number of observed events. Therefore in the absence of reliable evidence regarding the effectiveness and safety of the two surgical techniques for the management of vulval intraepithelial neoplasia precludes any definitive guidance or recommendations for clinical practice.

Entities:  

Mesh:

Year:  2011        PMID: 21249698      PMCID: PMC4170992          DOI: 10.1002/14651858.CD007928.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  31 in total

1.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

3.  Measuring sexual functioning in premenopausal women.

Authors:  A M Garratt; D J Torgerson; J Wyness; M H Hall; D M Reid
Journal:  Br J Obstet Gynaecol       Date:  1995-04

4.  Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial.

Authors:  Vivian E von Gruenigen; Heidi E Gibbons; Karen Gibbins; Eric L Jenison; Michael P Hopkins
Journal:  Obstet Gynecol       Date:  2007-04       Impact factor: 7.661

5.  Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithelial neoplasia.

Authors:  Amanda Tristram; Alison Fiander
Journal:  Gynecol Oncol       Date:  2005-09-16       Impact factor: 5.482

Review 6.  Vulval intraepithelial neoplasia: current perspectives.

Authors:  R W Jones
Journal:  Eur J Gynaecol Oncol       Date:  2001       Impact factor: 0.196

7.  Vulvar intraepithelial neoplasia III: a clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinoma.

Authors:  R W Jones; D M Rowan
Journal:  Obstet Gynecol       Date:  1994-11       Impact factor: 7.661

8.  Accuracy of preoperative vulva biopsy and the outcome of surgery in vulvar intraepithelial neoplasia 2 and 3.

Authors:  Stephan Polterauer; Anne Catharina Dressler; Christoph Grimm; Veronika Seebacher; Clemens Tempfer; Alexander Reinthaller; Lukas Hefler
Journal:  Int J Gynecol Pathol       Date:  2009-11       Impact factor: 2.762

9.  Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study.

Authors:  Ole Mathiesen; Sanne K Buus; Marie Cramers
Journal:  Gynecol Oncol       Date:  2007-07-25       Impact factor: 5.482

10.  Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia.

Authors:  Tien Le; Chantal Menard; Wendy Hicks-Boucher; Laura Hopkins; Johanne Weberpals; Michael Fung-Kee-Fung
Journal:  Gynecol Oncol       Date:  2007-06-19       Impact factor: 5.482

View more
  3 in total

Review 1.  Medical interventions for high grade vulval intraepithelial neoplasia.

Authors:  Litha Pepas; Sonali Kaushik; Andrew Bryant; Andy Nordin; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

2.  Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women.

Authors:  Elizabeth A Stier; Stephen E Goldstone; Mark H Einstein; Naomi Jay; John M Berry; Timothy Wilkin; Jeannette Y Lee; Teresa M Darragh; Maria Da Costa; Lori Panther; David Aboulafia; Joel M Palefsky
Journal:  AIDS       Date:  2013-02-20       Impact factor: 4.177

3.  Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence.

Authors:  J J Wallbillich; H E Rhodes; A M Milbourne; M F Munsell; M Frumovitz; J Brown; C L Trimble; K M Schmeler
Journal:  Gynecol Oncol       Date:  2012-08-04       Impact factor: 5.482

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.